409 related articles for article (PubMed ID: 32813123)
1. Infliximab in young paediatric IBD patients: it is all about the dosing.
Jongsma MME; Winter DA; Huynh HQ; Norsa L; Hussey S; Kolho KL; Bronsky J; Assa A; Cohen S; Lev-Tzion R; Van Biervliet S; Rizopoulos D; de Meij TGJ; Shouval DS; Wine E; Wolters VM; Martinez-Vinson C; de Ridder L;
Eur J Pediatr; 2020 Dec; 179(12):1935-1944. PubMed ID: 32813123
[TBL] [Abstract][Full Text] [Related]
2. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
3. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
[TBL] [Abstract][Full Text] [Related]
4. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
Borren NZ; Paulides E; Frinack JL; Olson RN; Willrich MAV; van der Woude CJ; Ananthakrishnan AN
Dig Dis Sci; 2021 Oct; 66(10):3548-3554. PubMed ID: 33037969
[TBL] [Abstract][Full Text] [Related]
5. Serum infliximab concentrations in pediatric inflammatory bowel disease.
Hämäläinen A; Sipponen T; Kolho KL
Scand J Gastroenterol; 2013 Jan; 48(1):35-41. PubMed ID: 23148710
[TBL] [Abstract][Full Text] [Related]
6. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease.
Choi SY; Kang B; Lee JH; Choe YH
Gut Liver; 2017 Jan; 11(1):55-61. PubMed ID: 27609485
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
[TBL] [Abstract][Full Text] [Related]
9. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort.
Azzam N; Aljebreen A; Alharbi O; Charabaty A; Alanazi M; Alkuwaykibi N; Alfaraidi J; Bashamil A; Almansour T; Almadi M
Arab J Gastroenterol; 2021 Mar; 22(1):66-72. PubMed ID: 33632623
[TBL] [Abstract][Full Text] [Related]
10. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
12. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
[TBL] [Abstract][Full Text] [Related]
13. Infliximab levels and antibodies in IBD-related peripheral arthralgia.
Levartovsky A; Ungar B; Yavzori M; Picard O; Fudim E; Eliakim R; Paul S; Roblin X; Ben-Horin S; Kopylov U
Int J Colorectal Dis; 2020 Jun; 35(6):1141-1148. PubMed ID: 32296932
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease.
Buhl S; Dorn-Rasmussen M; Brynskov J; Ainsworth MA; Bendtzen K; Klausen PH; Bolstad N; Warren DJ; Steenholdt C
Scand J Gastroenterol; 2020 Aug; 55(8):884-890. PubMed ID: 32631131
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
[TBL] [Abstract][Full Text] [Related]
16. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.
Bauman LE; Xiong Y; Mizuno T; Minar P; Fukuda T; Dong M; Rosen MJ; Vinks AA
Inflamm Bowel Dis; 2020 Feb; 26(3):429-439. PubMed ID: 31287855
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial.
Strik AS; Löwenberg M; Mould DR; Berends SE; Ponsioen CI; van den Brande JMH; Jansen JM; Hoekman DR; Brandse JF; Duijvestein M; Gecse KB; de Vries A; Mathôt RA; D'Haens GR
Scand J Gastroenterol; 2021 Feb; 56(2):145-154. PubMed ID: 33290108
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings.
Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Williams AJ; Ng W; Connor S
Intern Med J; 2021 May; 51(5):739-745. PubMed ID: 31589357
[TBL] [Abstract][Full Text] [Related]
20. Safety and Durability of Accelerated Infliximab Dosing Strategies in Pediatric IBD: A Single Center, Retrospective Study.
Gibson M; Subedi S; Barker DH; Masur S; Mallette MM; Lingannan A; Recinos Soto AA; Esharif D; Maxwell SH; Riaz MS; Herzlinger MI; Shalon LB; Cerezo CS; Kasper VL; Ross AM; Leleiko NS; Shapiro JM
J Pediatr Gastroenterol Nutr; 2023 Aug; 77(2):207-213. PubMed ID: 37084343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
